Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABOS
Strong SellHot AirAcumen Pharmaceuticals, Inc. · Healthcare · United States · $211M · Avg Vol: $993K/d
COMPANY DESCRIPTION
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. The company concentrates on a highly specific target (amyloid-beta oligomers) with its lead candidate, ACU90, aiming to address the underlying pathology of Alzheimer's. Acumen Pharmaceuticals is a focused biopharmaceutical firm in the high-risk, high-reward Alzheimer's therapeutic space, pursuing innovative disease modification approaches.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -5.02 | -1.06 | -1.08 | -1.71 | -2.00 | — | -1.64 | -1.59 | -1.43 | — |
| Shares | 40.5M | 41.0M | 57.9M | 60.1M | 60.6M | +49.7% | 72.3M | — | — | — |
| Debt | 0 | 0.1M | 28.5M | 28.7M | 31.3M | 568.1% | 31.6M | — | — | — |
| Equity | 225.2M | 188.8M | 267.0M | 181.8M | 70.4M | -25.2% | — | — | — | — |
| Op CF | -18.0M | -35.2M | -43.1M | -86.2M | -115.5M | — | -91.8M | — | — | — |
| Inv CF | -104.1M | 39.2M | -171.7M | 48.0M | 133.9M | — | — | — | — | — |
| Fin CF | 200.5M | 3.9M | 151.8M | 6.9M | -34.0K | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABOS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABOS | Acumen Pharmaceuticals, Inc.(you) | $211M | 13 | Strong Sell |
| CHRS | Coherus Oncology, Inc. | $218M | 13 | Strong Sell |
| PEPG | PepGen Inc. | $213M | 14 | Strong Sell |
| VYGR | Voyager Therapeutics, Inc. | $218M | 14 | Strong Sell |
| KROS | Keros Therapeutics, Inc. | $219M | 15 | Strong Sell |
| NBP | NovaBridge Biosciences | $213M | 10 | Strong Sell |
| NERV | Minerva Neurosciences, Inc. | $231M | 11 | Strong Sell |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $233M | 15 | Strong Sell |
| RNA | Atrium Therapeutics, Inc. | $233M | 11 | Strong Sell |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $211M | 8 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%